Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(TSX:SVA)

0.1550 +0.0050 (+3.33%)
Streaming Delayed Price Updated: 3:59 PM EDT, Jul 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about SVA

< Previous 1 2 3 Next >
CORRECTING and REPLACING SAIF Partners: Now is Your Last Chance to Vote for Board Change at Sinovac
From SAIF Partners IV L.P.
Via Business Wire
United States District Court of Massachusetts Bars Activist 1Globe Capital and Jiaqiang Li From Making Further Materially Misleading Statements Regarding Sinovac
From Vivo Capital
Via Business Wire
SAIF Partners Sends Letter to Sinovac Shareholders
From SAIF Partners IV L.P.
Via Business Wire
Sernova Announces Key New Executive Appointments
Experienced leadership team positions company to advance Cell Pouch™ bio-hybrid organ programs. 
Via TheNewswire.com
SAIF Partners Sends Open Letter to Sinovac Shareholders Outlining Current Board’s Failure to Act in the Interests of Shareholders
From SAIF Partners IV L.P.,
Via Business Wire
Prime Success Issues Statement on New York State Court Decision Confirming Our Rights as Sinovac Shareholders – Including Right to Vote at Upcoming Special Meeting
From Prime Success L.P.
Via Business Wire
SINOVAC Announces New Board Member
From Sinovac Biotech Ltd.
Via Business Wire
Prime Success Sets the Record Straight Regarding Continued False and Misleading Statements from Sinovac Biotech’s Current Board
From Prime Success L.P.
Via Business Wire
SAIF Partners Files Definitive Proxy Materials in Connection with Sinovac Biotech 2025 Special Meeting of Shareholders; Nominates Ten Highly Qualified Director Candidates to the Board
From SAIF Partners IV L.P.
Via Business Wire
SINOVAC Board of Directors Alerts Shareholders to Advantech/Prime Success’ New Lawsuit, Which Threatens to Prevent Payment of US$55.00 Special Dividend to All Valid Shareholders
From SINOVAC Biotech Ltd.
Via Business Wire
Prime Success Responds to Sinovac Biotech’s False and Misleading Claims
From Prime Success L.P.
Via Business Wire
SINOVAC’s Board of Directors Issues a Letter to Shareholders Outlining Clear Pathway to Restore Fairness and Deliver Value to All Shareholders
From Sinovac Biotech Ltd.
Via Business Wire
Vivo Capital Issues Letter to Sinovac Biotech Shareholders Addressing the Company’s False and Misleading Claims
From Vivo Capital
Via Business Wire
Prime Success Sends Letter to Sinovac Biotech Shareholders
From Prime Success L.P.
Via Business Wire
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2024 Annual Report
From Sinovac Biotech Ltd.
Via Business Wire
SINOVAC Announces Record and Distribution Dates for Special Cash Dividend
From Sinovac Biotech Ltd.
Via Business Wire
SINOVAC Board Issues Letter to Shareholders to Set the Record Straight on the Hostile Actions and False Claims by Vivo Capital
From Sinovac Biotech Ltd.
Via Business Wire
Vivo Capital Files Lawsuits to Protect Sinovac Shareholders from the New Board’s Value Destructive Actions
From Vivo Capital
Via Business Wire
SINOVAC Announces Decision to Declare Cash Dividend
From Sinovac Biotech Ltd.
Via Business Wire
SINOVAC Announces New Board Member and Chairman of the Audit Committee
From Sinovac Biotech Ltd.
Via Business Wire
SINOVAC Announces New Board Pursuant to Privy Council Judgment and Order
From Sinovac Biotech Ltd.
Via Business Wire
SINOVAC Issues Statement Regarding Privy Council Judgment
From Sinovac Biotech Ltd.
Via Business Wire
SINOVAC Initiated a Phase III Clinical Trial on Bivalent Vaccine Against Hand Foot and Mouth Disease (HFMD)
From Sinovac Biotech Ltd.
Via Business Wire
Sernova to Present at the 2024 Cell & Gene Meeting on the Mesa
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
SINOVAC Reports Unaudited First Half of 2024 Financial Results
From Sinovac Biotech Ltd.
Via Business Wire
SINOVAC Reports Unaudited Second Half of 2023 Financial Results and Files 2023 Annual Report on Form 20-F
From Sinovac Biotech Ltd.
Via Business Wire
Sernova Provides Positive Clinical and Platform Portfolio Update
With recent positive findings in post-surgical hypothyroidism large animal study, Sernova anticipates filing an Investigational New Drug (IND) application in 2024 
Via TheNewswire.com
Sinovac Amends Shareholder Rights Plan
From Sinovac Biotech Ltd.
Via Business Wire
Sinovac Board of Directors Unanimously Rejects an Unsolicited Partial Tender Offer
From Sinovac Biotech Ltd.
Via Business Wire
SINOVAC Reports on the Clinical Trial Progress of its Anti-COVID-19 Antibody SA55 Injection
From Sinovac Biotech Ltd.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.